Asset profile
tirzepatide · Zepbound / Mounjaro
Peptide
Approvedregulatory verdict
Evidence outlook
Approved: Type 2 Diabetes, Obesity
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
Also in development:Atherosclerotic Cardiovascular Disease
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
177 competitors in this universe: 11 direct rivals (same mechanism and indication), 1 same-class, 165 same-indication.
Unlock with Research ↗
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Tirzepatide (Zepbound / Mounjaro): this drug | Approved | Peptide | GLP-1/GIP receptor (dual) | ||
| BGM0504 | Phase 3 | Peptide | GLP-1/GIP receptor (dual) | ||
| Brenipatide | Phase 3 | Peptide | GLP-1/GIP receptor (dual) | ||
| Enicepatide | Phase 3 | Peptide | GLP-1 receptor, GLP-1/GIP receptor (dual) | ||
| HDM1005 | Phase 3 | Peptide | GLP-1/GIP receptor (dual) | ||
| HS-20094 | Phase 3 | Peptide | GLP-1/GIP receptor (dual) | ||
| RAY1225 | Phase 3 | Peptide | GLP-1/GIP receptor (dual) | ||
| Ribupatide | Phase 3 | Peptide | GLP-1/GIP receptor (dual) | ||
| VK2735 | Phase 3 | Peptide | GLP-1/GIP receptor (dual) | ||
| NNC0519-0130 | Phase 2 | Peptide | GLP-1/GIP receptor (dual) | ||
| Olatorepatide | Phase 2 | Peptide | GLP-1/GIP receptor (dual) | ||
| THDBH120 | Phase 2 | Peptide | GLP-1/GIP receptor (dual) | ||
| KP405 | Phase 1 | Peptide | GLP-1/GIP receptor (dual) | ||
| Afrezza | Approved | Peptide | Insulin receptor (basal), Insulin | ||
| Alirocumab (Praluent) | Approved | Monoclonal antibody | PCSK9 | ||
| Alogliptin (Nesina) | Approved | Small molecule | DPP-4 |
…and 162 more. Research shows the complete landscape.
Research
Unlock with Research ↗Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
vs BGM0504 · Obesityvs enicepatide · Obesityvs HS-20094 · Obesityvs ribupatide · Obesity +1vs VK2735 · Obesity +1vs NNC0519-0130 · Obesity
5 further head-to-head pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(113 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (12)
November 2026 (4)
Phase 1Type 2 DiabetesActive not recruiting
Est. primary completion 2026-11 · NCT07299084 · CT.gov ↗
What to watch
Phase 3ObesityActive not recruiting
Est. primary completion 2026-11 · NCT06962280 · CT.gov ↗
What to watch
Phase 3ObesityActive not recruiting
Est. primary completion 2026-11 · NCT06914895 · CT.gov ↗
What to watch
Early phase / not applicableObesityRecruiting
Est. primary completion 2026-11-23 · NCT07740291 · CT.gov ↗
What to watch
December 2026 (8)
Phase 2Long COVIDActive not recruiting
Est. primary completion 2026-12 · NCT07128082 · CT.gov ↗
What to watch
Phase 3ObesityNot yet recruiting
Est. primary completion 2026-12 · NCT07298915 · CT.gov ↗
What to watch
Early phase / not applicableObesityRecruiting
Est. primary completion 2026-12 · NCT07373834 · CT.gov ↗
What to watch
Phase 1Diabetes, Prostate CancerRecruiting
Est. primary completion 2026-12-31 · NCT06759701 · CT.gov ↗
What to watch
Phase 4ObesityEnrolling by invitation
Est. primary completion 2026-12-31 · NCT07057310 · CT.gov ↗
What to watch
2027 (52)
January 2027 (3)
Early phase / not applicableObesityRecruiting
Est. primary completion 2027-01 · NCT07364175 · CT.gov ↗
What to watch
Phase 2/3ObesityActive not recruiting
Est. primary completion 2027-01-01 · NCT06162715 · CT.gov ↗
What to watch
Early phase / not applicableType 2 DiabetesNot yet recruiting
Est. primary completion 2027-01-12 · NCT07728318 · CT.gov ↗
What to watch
February 2027 (5)
Phase 2Endometrial Cancer, Atypical HyperplasiaNot yet recruiting
Est. primary completion 2027-02 · NCT06073184 · CT.gov ↗
What to watch
Phase 3Type 2 DiabetesRecruiting
Est. primary completion 2027-02-14 · NCT07481747 · CT.gov ↗
What to watch
Early phase / not applicableObesityActive not recruiting
Est. primary completion 2027-02-15 · NCT06484114 · CT.gov ↗
What to watch
March 2027 (5)
Phase 2Alcohol Use Disorder (AUD)Recruiting
Est. primary completion 2027-03-01 · NCT06727331 · CT.gov ↗
What to watch
Early phase / not applicableLax SkinActive not recruiting
Est. primary completion 2027-03-01 · NCT07685834 · CT.gov ↗
What to watch
Phase 4Crohn DiseaseRecruiting
Est. primary completion 2027-03-05 · NCT06774079 · CT.gov ↗
What to watch
Phase 4Atherosclerotic Cardiovascular DiseaseRecruiting
Est. primary completion 2027-03-20 · NCT06606821 · CT.gov ↗
What to watch
Phase 1Colorectal Cancer Prevention, Colorectal AdenomaRecruiting
Est. primary completion 2027-03-31 · NCT07095517 · CT.gov ↗
What to watch
April 2027 (5)
Phase 4Cardiovascular DiseasesNot yet recruiting
Est. primary completion 2027-04 · NCT07483801 · CT.gov ↗
What to watch
Early phase / not applicableObesityRecruiting
Est. primary completion 2027-04-02 · NCT07293325 · CT.gov ↗
What to watch
Phase 4ObesityActive not recruiting
Est. primary completion 2027-04-28 · NCT06854614 · CT.gov ↗
What to watch
May 2027 (4)
Phase 2Type 2 DiabetesRecruiting
Est. primary completion 2027-05 · NCT06897475 · CT.gov ↗
What to watch
Phase 2ObesityNot yet recruiting
Est. primary completion 2027-05-15 · NCT07292519 · CT.gov ↗
What to watch
June 2027 (2)
July 2027 (4)
Phase 2ObesityNot yet recruiting
Est. primary completion 2027-07 · NCT07671391 · CT.gov ↗
What to watch
Phase 4Type 2 DiabetesActive not recruiting
Est. primary completion 2027-07 · NCT07438444 · CT.gov ↗
What to watch
Phase 4ObesityActive not recruiting
Est. primary completion 2027-07-01 · NCT06803888 · CT.gov ↗
What to watch
Phase 2Metabolic Alcohol-associated Liver Disease, Alcohol Use DisorderRecruiting
Est. primary completion 2027-07-30 · NCT07046819 · CT.gov ↗
What to watch
August 2027 (4)
Phase 4Idiopathic Intracranial Hypertension (IIH)Recruiting
Est. primary completion 2027-08 · NCT07191873 · CT.gov ↗
What to watch
Phase 4ObesityActive not recruiting
Est. primary completion 2027-08 · NCT06864026 · CT.gov ↗
What to watch
Phase 4Type 2 DiabetesRecruiting
Est. primary completion 2027-08-10 · NCT07588438 · CT.gov ↗
What to watch
Phase 2ObesityNot yet recruiting
Est. primary completion 2027-08-15 · NCT06732245 · CT.gov ↗
What to watch
September 2027 (8)
Phase 1ObesityActive not recruiting
Est. primary completion 2027-09 · NCT06734273 · CT.gov ↗
What to watch
Phase 4Pouch, Ileal, Pouches, Ileoanal, Bowel Diseases, InflammatoryNot yet recruiting
Est. primary completion 2027-09 · NCT07756359 · CT.gov ↗
What to watch
Phase 2Hormone Receptor-Positive Breast Cancer, HER2-Negative Breast CancerRecruiting
Est. primary completion 2027-09-30 · NCT06518837 · CT.gov ↗
What to watch
Phase 2Opioid Use Disorder, Opioid Use Disorder, Moderate, Opioid Use Disorder, SevereRecruiting
Est. primary completion 2027-09-30 · NCT06651177 · CT.gov ↗
What to watch
October 2027 (3)
Phase 3ObesityActive not recruiting
Est. primary completion 2027-10 · NCT05556512 · CT.gov ↗
What to watch
Phase 4ObesityActive not recruiting
Est. primary completion 2027-10-30 · NCT06861439 · CT.gov ↗
What to watch
November 2027 (2)
December 2027 (7)
Phase 1Endometrial CancerRecruiting
Est. primary completion 2027-12 · NCT06751589 · CT.gov ↗
What to watch
Phase 4Atherosclerotic Cardiovascular DiseaseEnrolling by invitation
Est. primary completion 2027-12 · NCT07707778 · CT.gov ↗
What to watch
Phase 4Type 2 DiabetesRecruiting
Est. primary completion 2027-12-15 · NCT06657209 · CT.gov ↗
What to watch
Phase 2Type 1 Diabetes MellitusRecruiting
Est. primary completion 2027-12-31 · NCT06820281 · CT.gov ↗
What to watch
Early phase / not applicableObesityNot yet recruiting
Est. primary completion 2027-12-31 · NCT07382024 · CT.gov ↗
What to watch
2028 (31)
January 2028 (3)
Phase 2Endometrial CancerNot yet recruiting
Est. primary completion 2028-01 · NCT07605247 · CT.gov ↗
What to watch
Phase 2/3Type 1 Diabetes, Type 1 Diabetes Mellitus, T1D, T1DM, T1DM - Type 1 Diabetes MellitusRecruiting
Est. primary completion 2028-01 · NCT07284511 · CT.gov ↗
What to watch
Phase 4ObesityActive not recruiting
Est. primary completion 2028-01-31 · NCT06801015 · CT.gov ↗
What to watch
February 2028 (3)
Early phase / not applicableObesityRecruiting
Est. primary completion 2028-02 · NCT07443956 · CT.gov ↗
What to watch
Early phase / not applicableDrug Discontinuation, Substance Use Disorders, Eating Behavior Changes, TirzepatideRecruiting
Est. primary completion 2028-02 · NCT07387796 · CT.gov ↗
What to watch
March 2028 (3)
Phase 2Smoking Cessation, Smoking BehaviorsRecruiting
Est. primary completion 2028-03 · NCT07602699 · CT.gov ↗
What to watch
Phase 2Hormone-receptor-positive Breast Cancer, Early Breast CancerNot yet recruiting
Est. primary completion 2028-03-01 · NCT07676331 · CT.gov ↗
What to watch
Phase 2Cannabis Use DisorderNot yet recruiting
Est. primary completion 2028-03-15 · NCT07468552 · CT.gov ↗
What to watch
April 2028 (2)
May 2028 (6)
Phase 2Crohn Disease (CD)Recruiting
Est. primary completion 2028-05 · NCT06976853 · CT.gov ↗
What to watch
Early phase / not applicableObesityRecruiting
Est. primary completion 2028-05-01 · NCT07633639 · CT.gov ↗
What to watch
Phase 2Central Centrifugal Cicatricial Alopecia (CCCA)Recruiting
Est. primary completion 2028-05-25 · NCT07734870 · CT.gov ↗
What to watch
Phase 2/3Acute Ischemic Stroke (AIS)Not yet recruiting
Est. primary completion 2028-05-31 · NCT07734792 · CT.gov ↗
What to watch
June 2028 (2)
July 2028 (4)
Phase 4Neuropathy, Small Fiber, Diabete MellitusNot yet recruiting
Est. primary completion 2028-07-01 · NCT07706088 · CT.gov ↗
What to watch
Phase 2Mild Autonomous Cortisol Secretion (MACS), Adrenalectomy; StatusRecruiting
Est. primary completion 2028-07-31 · NCT07573163 · CT.gov ↗
What to watch
Phase 3Cannabis Use Disorder, Moderate, Cannabis Use Disorder, SevereNot yet recruiting
Est. primary completion 2028-07-31 · NCT07671248 · CT.gov ↗
What to watch
August 2028 (2)
September 2028 (1)
Early phase / not applicableObesityRecruiting
Est. primary completion 2028-09-30 · NCT07589322 · CT.gov ↗
What to watch
December 2028 (5)
Phase 2ObesityNot yet recruiting
Est. primary completion 2028-12 · NCT06180616 · CT.gov ↗
What to watch
Phase 3ObesityNot yet recruiting
Est. primary completion 2028-12 · NCT07829198 · CT.gov ↗
What to watch
Phase 2/3ObesityNot yet recruiting
Est. primary completion 2028-12-01 · NCT07846865 · CT.gov ↗
What to watch
2029 (13)
March 2029 (1)
Phase 2Endometrial Cancer, Endometrial Intraepithelial Neoplasia, Grade 1 Endometrial Endometrioid CarcinomaNot yet recruiting
Est. primary completion 2029-03 · NCT07078838 · CT.gov ↗
What to watch
April 2029 (2)
May 2029 (1)
Early phase / not applicableObesityRecruiting
Est. primary completion 2029-05-15 · NCT07574723 · CT.gov ↗
What to watch
June 2029 (1)
July 2029 (1)
August 2029 (3)
Phase 4Atrial Fibrillation, Heart Failure With Preserved Ejection Fraction (HFpEF), TirzepatideNot yet recruiting
Est. primary completion 2029-08-01 · NCT07630454 · CT.gov ↗
What to watch
Early phase / not applicableObesityRecruiting
Est. primary completion 2029-08-30 · NCT06885736 · CT.gov ↗
What to watch
Phase 2Breast Cancer, Breast Neoplasms, Breast CancersRecruiting
Est. primary completion 2029-08-31 · NCT06517212 · CT.gov ↗
What to watch
September 2029 (2)
October 2029 (1)
Phase 2Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia, FIGO Grade 1 Endometrial Endometrioid AdenocarcinomaNot yet recruiting
Est. primary completion 2029-10-31 · NCT07349641 · CT.gov ↗
What to watch
December 2029 (1)
Phase 3ObesityNot yet recruiting
Est. primary completion 2029-12 · NCT07817875 · CT.gov ↗
What to watch
2030 (4)
February 2030 (1)
Phase 2ObesityEnrolling by invitation
Est. primary completion 2030-02-01 · NCT07693608 · CT.gov ↗
What to watch
March 2030 (1)
Phase 2Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)Recruiting
Est. primary completion 2030-03-15 · NCT07527910 · CT.gov ↗
What to watch
June 2030 (1)
Phase 1Lung CancerNot yet recruiting
Est. primary completion 2030-06 · NCT07782359 · CT.gov ↗
What to watch
August 2030 (1)
Phase 3Metabolic Dysfunction-Associated Steatotic Liver DiseaseRecruiting
Est. primary completion 2030-08 · NCT07165028 · CT.gov ↗
What to watch
2031 (1)
December 2031 (1)
Phase 1Alcohol Use Disorder (AUD)Recruiting
Est. primary completion 2031-12-31 · NCT07559500 · CT.gov ↗
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.